Profile photo

Lung Cancers With Coral Olazagasti, MD

Oncology / Hematology

Dr. Coral Olazagasti is a medical oncologist and Assistant Professor at the Sylvester Comprehensive Cancer Center, University of Miami. She specializes in head and neck as well as thoracic malignancies. Dr. Olazagasti earned her medical degree from the Universidad Central del Caribe in Bayamón, Puerto Rico.

DeLLphi 301 is a Game-Changer in NSCLC Research: Learn More From ASCO 2025

Dear readers,

After the promising results of IMforte, what better time to spotlight another game-changer in small cell lung cancer (SCLC): the DeLLphi 301 trial. This pivotal Phase 3 study evaluated the DLL3-targeted bispecific T-cell engager tarlatamab versus standard chemotherapy in patients with SCLC following progression on platinum-based therapy. Key findings are a Median Progression-Free Survival (PFS) with Tarlatamab of 4.2 months vs 3.2 months with Chemotherapy. Overall Response Rate (ORR) of 35% vs 20%, and a Median Duration of Response (DoR) of 6.9 months vs 5.5 months. In a landscape where treatment options have been limited and survival gains marginal, tarlatamab demonstrates meaningful clinical benefit in the second-line setting. These data firmly position tarlatamab as a new standard of care in relapsed SCLC.
With IMforte advancing maintenance therapy and DeLLphi 301 raising the bar for second-line treatment, we are surely entering a new era for SCLC.
Sincerely,
Coral Olazagasti, MD
Articles
  • Mashup Score: 138
    • Profile photo of StephenVLiu
      StephenVLiu

      #ASCO25 Dr. @charlesrudin presents interim analysis of DeLLphi-304: randomized phase II study of tarlatamab (DLL3 TCE) vs 2L chemo in #SCLC. Chemo was mostly topotecan; 45% of pts were platinum resistant. Clear OS benefit with HR 0.60 (13.6m vs 8.3m). PFS 4.2 vs 3.7m, HR 0.71. https://t.co/2sJvZxxSei

      Read the original tweet here

    Tweet Tweets with this article
  • Mashup Score: 63
    • Profile photo of jennifermarksmd
      jennifermarksmd

      Certainly agree with @JordiRemon that DELLI was a very brave study; it appears though that ultra-low dose of IO still provides OS benefit when compared to
      chemo in ≥ 2L. Masterful presentation as usual.
      #ASCO25 @ASCO #lcsm #lcam https://t.co/vioEnma1tW

      Read the original tweet here

    Tweet Tweets with this article
  • Mashup Score: 31
    • Profile photo of lungoncdoc
      lungoncdoc

      #DeLLphi304 results as presented by @charlesrudin here at #ASCO25 — how best to sequence our treatment options in ES-SCLC after disease progression on chemoimmunotherapy?

      @SclcSMASHERS https://t.co/ahd9PAXs9h

      Read the original tweet here

    Tweet Tweets with this article
  • Mashup Score: 276
    • Profile photo of g_mountzios
      g_mountzios

      #ASCO25 After 30 years of failed trials, #tarlatamab changes SoC for our pts with relapsed #SCLC :

      ✅ mOS: 13.6 vs 8.3 months, HR=0.6, p<0.001
      ✅ improved QoL (dyspnea and cough)
      ✅ 27% vs 62% G3 TRAEs

      Grateful to all collaborators, @Amgen science team and above all our pts https://t.co/knM4KuS0wV

      Read the original tweet here

    Tweet Tweets with this article